English

Asterias Biotherapeutics, Inc.

EDGAR

Filing amendment (SC 13D/A) · filed 2019-03-12

29 filing records in this dataset, filed from 2013-04-03 to 2019-03-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

116 thousand U002

2018 Q3 · U002

Exact inputs and evidence

Revenue: 116000 U002 Source

Operating margin

-4,621.55%

2018 Q3 · %

Exact inputs and evidence

Operating Income: -5361000 U002 Source
Revenue: 116000 U002 Source

Operating cash flow

-2.91 million U002

2018 Q3 · U002

Exact inputs and evidence

Operating Cash Flow: -10037000 U002 Source
Operating Cash Flow: -7129000 U002 Source

Free cash flow

-2.91 million U002

2018 Q3 · U002

Exact inputs and evidence

Operating Cash Flow: -10037000 U002 Source
Operating Cash Flow: -7129000 U002 Source
Capital Expenditure: 0 U002 Source
Capital Expenditure: 0 U002 Source

Cash and cash equivalents: 6.42 million U002 2018-09-30 Source
Exact value

6424000 U002
Long-term debt including current maturities: Not available
Shares outstanding: 30.9 million U002 2014-12-31 Source
Exact value

30902152 U002

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-03-12.

Financial data available through: 2017-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2017-12-31
Operating income: 5 of 11 periods available· newest 2017-12-31
Net income: 6 of 11 periods available· newest 2017-12-31
Operating cash flow: 5 of 11 periods available· newest 2017-12-31
Capital expenditure: 5 of 11 periods available· newest 2017-12-31
Total assets: Multiple units; comparison withheld· newest 2017-12-31
Total liabilities: Multiple units; comparison withheld· newest 2017-12-31
Current assets: Multiple units; comparison withheld· newest 2017-12-31
Current liabilities: Multiple units; comparison withheld· newest 2017-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2017-12-31
long term debt: No compatible figures in this window
Shares outstanding: 1 of 11 periods available· newest 2014-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-41.9%

Prior period

U001 6.95 million

2016-01-01 – 2016-12-31
Current period

U001 4.04 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

4042000 − 6954000 = -2912000 U001

6954000 U001 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
4042000 U001 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Year-over-year change in Revenue: -2912000 U001 Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4042000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#624309 Filing: 000114036118013695 Input fundies:Revenue: 6954000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#624182 Filing: 000114036118013695
The citation records this snapshot. The page link may show a newer release later.
Net income
+U001 7.12 million

Prior period

−U001 35.49 million

2016-01-01 – 2016-12-31
Current period

−U001 28.37 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-28372000 − -35489000 = 7117000 U001

-35489000 U001 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-28372000 U001 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Year-over-year change in Net income: 7117000 U001 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -28372000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508450 Filing: 000114036118013695 Input fundies:NetIncome: -35489000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508311 Filing: 000114036118013695
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−U001 5.43 million

Prior period

−U001 19.01 million

2016-01-01 – 2016-12-31
Current period

−U001 24.44 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-24437000 − -19008000 = -5429000 U001

-19008000 U001 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-24437000 U001 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Year-over-year change in Operating cash flow: -5429000 U001 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -24437000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508114 Filing: 000114036118013695 Input fundies:OperatingCashFlow: -19008000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#507634 Filing: 000114036118013695
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-67.6%

Prior period

U001 894,000

2016-01-01 – 2016-12-31
Current period

U001 290,000

2017-01-01 – 2017-12-31

Exact inputs and evidence

290000 − 894000 = -604000 U001

894000 U001 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
290000 U001 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Year-over-year change in Capital expenditure: -604000 U001 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 290000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#555051 Filing: 000114036118013695 Input fundies:CapitalExpenditure: 894000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#554815 Filing: 000114036118013695
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue U001 4.04 million 100% of revenue
Cost of revenue U001 165,000 4.1% of revenue
Operating expenses U001 37.13 million 919% of revenue
Operating income −U001 33.25 million −823% of revenue
Tax, interest and other Derived −U001 4.88 million −121% of revenue
Net income −U001 28.37 million −702% of revenue

Cash

Operating cash flow −U001 24.44 million −605% of revenue
Capital expenditure U001 290,000 7.2% of revenue
Free cash flow Derived −U001 24.73 million −612% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Not shown: operating income or net income is not reported.
2014 Operating loss: operating costs were 1,527% of revenue.
2015 Operating loss: operating costs were 712% of revenue.
2016 Operating loss: operating costs were 591% of revenue.
2017 Operating loss: operating costs were 923% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	0	25661000 Derived	-25661000	-3281000 Derived	-22380000	-2574000 Derived	Source 2013-01-01 – 2013-12-31: 0 U001 Inspect Revenue Open source 2013-01-01 – 2013-12-31: -25661000 U001 Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -22380000 U001 Inspect Net Income Open source 2013-01-01 – 2013-12-31: -1327000 U001 Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1247000 U001 Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	1224000	18685000 Derived	-17461000	-7364000 Derived	-10097000	-11706000 Derived	Source 2014-01-01 – 2014-12-31: 1224000 U001 Inspect Revenue Open source 2014-01-01 – 2014-12-31: -17461000 U001 Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -10097000 U001 Inspect Net Income Open source 2014-01-01 – 2014-12-31: -11591000 U001 Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 115000 U001 Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	3582000	25490000 Derived	-21908000	-6905000 Derived	-15003000	-12706000 Derived	Source 2015-01-01 – 2015-12-31: 3582000 U001 Inspect Revenue Open source 2015-01-01 – 2015-12-31: -21908000 U001 Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -15003000 U001 Inspect Net Income Open source 2015-01-01 – 2015-12-31: -12393000 U001 Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 313000 U001 Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	6954000	41077000 Derived	-34123000	1366000 Derived	-35489000	-19902000 Derived	Source 2016-01-01 – 2016-12-31: 6954000 U001 Inspect Revenue Open source 2016-01-01 – 2016-12-31: -34123000 U001 Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -35489000 U001 Inspect Net Income Open source 2016-01-01 – 2016-12-31: -19008000 U001 Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 894000 U001 Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	4042000	37293000 Derived	-33251000	-4879000 Derived	-28372000	-24727000 Derived	Source 2017-01-01 – 2017-12-31: 4042000 U001 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -33251000 U001 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -28372000 U001 Inspect Net Income Open source 2017-01-01 – 2017-12-31: -24437000 U001 Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 290000 U001 Inspect Capital Expenditure Open source

Amounts are exact, in U001.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

U001 4M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(U001)	Source evidence
20132013-12-31	Revenue	0	Revenue: 0 Open source
20142014-12-31	Revenue	1224000	Revenue: 1224000 Open source
20152015-12-31	Revenue	3582000	Revenue: 3582000 Open source
20162016-12-31	Revenue	6954000	Revenue: 6954000 Open source
20172017-12-31	Revenue	4042000	Revenue: 4042000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-41.9% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20142014-12-31	Year over year	No prior comparable period	Revenue: 1224000 Open source Revenue: 0 Open source
20152015-12-31	Year over year	192.6%	Revenue: 3582000 Open source Revenue: 1224000 Open source
20162016-12-31	Year over year	94.1%	Revenue: 6954000 Open source Revenue: 3582000 Open source
20172017-12-31	Year over year	-41.9%	Revenue: 4042000 Open source Revenue: 6954000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -822.6% 2017

Net margin -701.9% 2017

Free cash flow margin -611.8% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	Not reported	Operating Income: -25661000 Open source Revenue: 0 Open source
20142014-12-31	Operating margin	-1,426.6%	Operating Income: -17461000 Open source Revenue: 1224000 Open source
20152015-12-31	Operating margin	-611.6%	Operating Income: -21908000 Open source Revenue: 3582000 Open source
20162016-12-31	Operating margin	-490.7%	Operating Income: -34123000 Open source Revenue: 6954000 Open source
20172017-12-31	Operating margin	-822.6%	Operating Income: -33251000 Open source Revenue: 4042000 Open source
20132013-12-31	Net margin	Not reported	Net Income: -22380000 Open source Revenue: 0 Open source
20142014-12-31	Net margin	-824.9%	Net Income: -10097000 Open source Revenue: 1224000 Open source
20152015-12-31	Net margin	-418.8%	Net Income: -15003000 Open source Revenue: 3582000 Open source
20162016-12-31	Net margin	-510.3%	Net Income: -35489000 Open source Revenue: 6954000 Open source
20172017-12-31	Net margin	-701.9%	Net Income: -28372000 Open source Revenue: 4042000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1327000 Open source Capital Expenditure: 1247000 Open source
20142014-12-31	Free cash flow margin	-956.4%	Revenue: 1224000 Open source Operating Cash Flow: -11591000 Open source Capital Expenditure: 115000 Open source
20152015-12-31	Free cash flow margin	-354.7%	Revenue: 3582000 Open source Operating Cash Flow: -12393000 Open source Capital Expenditure: 313000 Open source
20162016-12-31	Free cash flow margin	-286.2%	Revenue: 6954000 Open source Operating Cash Flow: -19008000 Open source Capital Expenditure: 894000 Open source
20172017-12-31	Free cash flow margin	-611.8%	Revenue: 4042000 Open source Operating Cash Flow: -24437000 Open source Capital Expenditure: 290000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

U001 -24.4M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(U001)	Source evidence
20132013-12-31	Operating cash flow	-1327000	Operating Cash Flow: -1327000 Open source
20142014-12-31	Operating cash flow	-11591000	Operating Cash Flow: -11591000 Open source
20152015-12-31	Operating cash flow	-12393000	Operating Cash Flow: -12393000 Open source
20162016-12-31	Operating cash flow	-19008000	Operating Cash Flow: -19008000 Open source
20172017-12-31	Operating cash flow	-24437000	Operating Cash Flow: -24437000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

U001 -24.7M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(U001)	Source evidence
20132013-12-31	Free cash flow	-2574000	Operating Cash Flow: -1327000 Open source Capital Expenditure: 1247000 Open source
20142014-12-31	Free cash flow	-11706000	Operating Cash Flow: -11591000 Open source Capital Expenditure: 115000 Open source
20152015-12-31	Free cash flow	-12706000	Operating Cash Flow: -12393000 Open source Capital Expenditure: 313000 Open source
20162016-12-31	Free cash flow	-19902000	Operating Cash Flow: -19008000 Open source Capital Expenditure: 894000 Open source
20172017-12-31	Free cash flow	-24727000	Operating Cash Flow: -24437000 Open source Capital Expenditure: 290000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	No source recorded
2014-12-31	Liabilities / assets	Not reported	No source recorded
2015-12-31	Liabilities / assets	Not reported	No source recorded
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Current assets / current liabilities	Not reported	No source recorded
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
2015-12-31	Current assets / current liabilities	Not reported	No source recorded
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−U001 758,893 Exact value Exact value: -758893 U001 2012-01-01 – 2012-12-31: -758893 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2012-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -758893 U001 Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=U001&dimensions= Input fundies:NetIncome: -758893 U001 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036114013049/ast-20131231.xml#255977 Filing: 000114036114013049 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−U001 22.38 million Exact value Exact value: -22380000 U001 2013-01-01 – 2013-12-31: -22380000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2013-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -22380000 U001 Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=U001&dimensions= Input fundies:NetIncome: -22380000 U001 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036116059357/ast-20151231.xml#354860 Filing: 000114036116059357 The citation records this snapshot. The page link may show a newer release later.	−U001 1.33 million Exact value Exact value: -1327000 U001 2013-01-01 – 2013-12-31: -1327000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Asterias Biotherapeutics, Inc. · 2013-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Operating Cash Flow: -1327000 U001 Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -1327000 U001 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036116059357/ast-20151231.xml#354321 Filing: 000114036116059357 The citation records this snapshot. The page link may show a newer release later.	U001 1.25 million Exact value Exact value: 1247000 U001 2013-01-01 – 2013-12-31: 1247000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Asterias Biotherapeutics, Inc. · 2013-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Capital Expenditure: 1247000 U001 Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 1247000 U001 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036116059357/ast-20151231.xml#386077 Filing: 000114036116059357 The citation records this snapshot. The page link may show a newer release later.	−U001 2.57 million Calculation and evidence -1327000 − 1247000 U001 Exact free cash flow: -2574000 U001 2013-01-01 – 2013-12-31: -1327000 U001 · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1247000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Asterias Biotherapeutics, Inc. · 2013-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Free cash flow: -2574000 U001 Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1327000 U001 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036116059357/ast-20151231.xml#354321 Filing: 000114036116059357 Input fundies:CapitalExpenditure: 1247000 U001 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036116059357/ast-20151231.xml#386077 Filing: 000114036116059357 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−U001 10.1 million Exact value Exact value: -10097000 U001 2014-01-01 – 2014-12-31: -10097000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2014-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -10097000 U001 Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=U001&dimensions= Input fundies:NetIncome: -10097000 U001 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036117013626/ast-20161231.xml#424137 Filing: 000114036117013626 The citation records this snapshot. The page link may show a newer release later.	−U001 11.59 million Exact value Exact value: -11591000 U001 2014-01-01 – 2014-12-31: -11591000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Asterias Biotherapeutics, Inc. · 2014-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Operating Cash Flow: -11591000 U001 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -11591000 U001 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036117013626/ast-20161231.xml#423016 Filing: 000114036117013626 The citation records this snapshot. The page link may show a newer release later.	U001 115,000 Exact value Exact value: 115000 U001 2014-01-01 – 2014-12-31: 115000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Asterias Biotherapeutics, Inc. · 2014-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Capital Expenditure: 115000 U001 Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 115000 U001 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036117013626/ast-20161231.xml#459184 Filing: 000114036117013626 The citation records this snapshot. The page link may show a newer release later.	−U001 11.71 million Calculation and evidence -11591000 − 115000 U001 Exact free cash flow: -11706000 U001 2014-01-01 – 2014-12-31: -11591000 U001 · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 115000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Asterias Biotherapeutics, Inc. · 2014-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Free cash flow: -11706000 U001 Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11591000 U001 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036117013626/ast-20161231.xml#423016 Filing: 000114036117013626 Input fundies:CapitalExpenditure: 115000 U001 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036117013626/ast-20161231.xml#459184 Filing: 000114036117013626 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−U001 15 million Exact value Exact value: -15003000 U001 2015-01-01 – 2015-12-31: -15003000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2015-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -15003000 U001 Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=U001&dimensions= Input fundies:NetIncome: -15003000 U001 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508589 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 12.39 million Exact value Exact value: -12393000 U001 2015-01-01 – 2015-12-31: -12393000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Asterias Biotherapeutics, Inc. · 2015-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Operating Cash Flow: -12393000 U001 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -12393000 U001 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#507874 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	U001 313,000 Exact value Exact value: 313000 U001 2015-01-01 – 2015-12-31: 313000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Asterias Biotherapeutics, Inc. · 2015-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Capital Expenditure: 313000 U001 Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 313000 U001 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#554579 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 12.71 million Calculation and evidence -12393000 − 313000 U001 Exact free cash flow: -12706000 U001 2015-01-01 – 2015-12-31: -12393000 U001 · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 313000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Asterias Biotherapeutics, Inc. · 2015-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Free cash flow: -12706000 U001 Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12393000 U001 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#507874 Filing: 000114036118013695 Input fundies:CapitalExpenditure: 313000 U001 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#554579 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−U001 35.49 million Exact value Exact value: -35489000 U001 2016-01-01 – 2016-12-31: -35489000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2016-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -35489000 U001 Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=U001&dimensions= Input fundies:NetIncome: -35489000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508311 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 19.01 million Exact value Exact value: -19008000 U001 2016-01-01 – 2016-12-31: -19008000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Asterias Biotherapeutics, Inc. · 2016-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Operating Cash Flow: -19008000 U001 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -19008000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#507634 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	U001 894,000 Exact value Exact value: 894000 U001 2016-01-01 – 2016-12-31: 894000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Asterias Biotherapeutics, Inc. · 2016-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Capital Expenditure: 894000 U001 Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 894000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#554815 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 19.9 million Calculation and evidence -19008000 − 894000 U001 Exact free cash flow: -19902000 U001 2016-01-01 – 2016-12-31: -19008000 U001 · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 894000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Asterias Biotherapeutics, Inc. · 2016-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Free cash flow: -19902000 U001 Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19008000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#507634 Filing: 000114036118013695 Input fundies:CapitalExpenditure: 894000 U001 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#554815 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−U001 28.37 million Exact value Exact value: -28372000 U001 2017-01-01 – 2017-12-31: -28372000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Net Income: -28372000 U001 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=U001&dimensions= Input fundies:NetIncome: -28372000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508450 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 24.44 million Exact value Exact value: -24437000 U001 2017-01-01 – 2017-12-31: -24437000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Operating Cash Flow: -24437000 U001 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -24437000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508114 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	U001 290,000 Exact value Exact value: 290000 U001 2017-01-01 – 2017-12-31: 290000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Capital Expenditure: 290000 U001 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 290000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#555051 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.	−U001 24.73 million Calculation and evidence -24437000 − 290000 U001 Exact free cash flow: -24727000 U001 2017-01-01 – 2017-12-31: -24437000 U001 · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 290000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Asterias Biotherapeutics, Inc. · 2017-12-31 Asterias Biotherapeutics, Inc. (edgar:1572552) Free cash flow: -24727000 U001 Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1572552?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24437000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#508114 Filing: 000114036118013695 Input fundies:CapitalExpenditure: 290000 U001 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1572552/000114036118013695/ast-20171231.xml#555051 Filing: 000114036118013695 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

29 filings · 1,970 latest values · 1,970 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001572552, 1572552, edgar:1572552

Also known as Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation